ES2286129T3 - Uso de 2-alfa-metil-19-nor-20(s)-1-alfa,25-dihidroxivitamina d3 en sustitucion osea. - Google Patents
Uso de 2-alfa-metil-19-nor-20(s)-1-alfa,25-dihidroxivitamina d3 en sustitucion osea. Download PDFInfo
- Publication number
- ES2286129T3 ES2286129T3 ES01952566T ES01952566T ES2286129T3 ES 2286129 T3 ES2286129 T3 ES 2286129T3 ES 01952566 T ES01952566 T ES 01952566T ES 01952566 T ES01952566 T ES 01952566T ES 2286129 T3 ES2286129 T3 ES 2286129T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- methyl
- bone
- dihydroxyvitamin
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 5
- 238000011540 hip replacement Methods 0.000 claims abstract description 3
- 238000013150 knee replacement Methods 0.000 claims abstract description 3
- 239000011612 calcitriol Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 abstract description 46
- 230000000694 effects Effects 0.000 abstract description 17
- 230000004069 differentiation Effects 0.000 abstract description 6
- 208000001132 Osteoporosis Diseases 0.000 abstract description 4
- 201000004681 Psoriasis Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 abstract description 3
- 210000001616 monocyte Anatomy 0.000 abstract description 3
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 230000011164 ossification Effects 0.000 abstract description 2
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 abstract description 2
- 208000017520 skin disease Diseases 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 21
- 239000011575 calcium Substances 0.000 description 21
- 229910052791 calcium Inorganic materials 0.000 description 21
- 239000000203 mixture Substances 0.000 description 13
- 229930003316 Vitamin D Natural products 0.000 description 11
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 11
- 239000011710 vitamin D Substances 0.000 description 11
- 235000019166 vitamin D Nutrition 0.000 description 11
- 229940046008 vitamin d Drugs 0.000 description 11
- -1 vitamin compounds Chemical class 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 description 7
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000020964 calcitriol Nutrition 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000009806 oophorectomy Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- PKFBWEUIKKCWEW-WEZTXPJVSA-N (1r,3r)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 PKFBWEUIKKCWEW-WEZTXPJVSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000001483 mobilizing effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MBEVSMZJMIQVBG-UHFFFAOYSA-N 2-(hydroxymethyl)guanidine Chemical compound NC(N)=NCO MBEVSMZJMIQVBG-UHFFFAOYSA-N 0.000 description 2
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000002956 ash Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229960005084 calcitriol Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- HKXBNHCUPKIYDM-CGMHZMFXSA-N doxercalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C HKXBNHCUPKIYDM-CGMHZMFXSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000004765 promyelocyte Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 102000009310 vitamin D receptors Human genes 0.000 description 2
- 108050000156 vitamin D receptors Proteins 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- ZGLHBRQAEXKACO-XJRQOBMKSA-N 1alpha,25-dihydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C ZGLHBRQAEXKACO-XJRQOBMKSA-N 0.000 description 1
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241001125048 Sardina Species 0.000 description 1
- 201000006035 X-linked dominant hypophosphatemic rickets Diseases 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000000125 calcaemic effect Effects 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- PDXRQENMIVHKPI-UHFFFAOYSA-N cyclohexane-1,1-diol Chemical group OC1(O)CCCCC1 PDXRQENMIVHKPI-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000000324 molecular mechanic Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical class [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QHJWOSHIGFDANE-UHFFFAOYSA-N prop-2-enylphosphane Chemical compound PCC=C QHJWOSHIGFDANE-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000032349 type 2B vitamin D-dependent rickets Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003703 vitamin D2 derivatives Chemical class 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
- B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
- B22D17/20—Accessories: Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
- B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
- B22D17/20—Accessories: Details
- B22D17/22—Dies; Die plates; Die supports; Cooling equipment for dies; Accessories for loosening and ejecting castings from dies
- B22D17/2236—Equipment for loosening or ejecting castings from dies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
- B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
- B22D17/20—Accessories: Details
- B22D17/22—Dies; Die plates; Die supports; Cooling equipment for dies; Accessories for loosening and ejecting castings from dies
- B22D17/24—Accessories for locating and holding cores or inserts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mechanical Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/616,778 US6306844B1 (en) | 1997-03-17 | 2000-07-14 | Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength |
| US616778 | 2000-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2286129T3 true ES2286129T3 (es) | 2007-12-01 |
Family
ID=24470903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01952566T Expired - Lifetime ES2286129T3 (es) | 2000-07-14 | 2001-07-10 | Uso de 2-alfa-metil-19-nor-20(s)-1-alfa,25-dihidroxivitamina d3 en sustitucion osea. |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US6306844B1 (https=) |
| EP (1) | EP1305030B1 (https=) |
| JP (1) | JP4955895B2 (https=) |
| KR (1) | KR100572958B1 (https=) |
| CN (1) | CN1250225C (https=) |
| AT (1) | ATE359796T1 (https=) |
| AU (2) | AU7330301A (https=) |
| BR (1) | BR0112453A (https=) |
| CA (1) | CA2416187A1 (https=) |
| DE (1) | DE60127964T2 (https=) |
| DK (1) | DK1305030T3 (https=) |
| ES (1) | ES2286129T3 (https=) |
| IL (2) | IL153908A0 (https=) |
| MX (1) | MXPA03000405A (https=) |
| NZ (1) | NZ524018A (https=) |
| WO (1) | WO2002005824A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6392071B1 (en) * | 1997-03-17 | 2002-05-21 | Wisconsin Alumni: Research Foundation | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds |
| MXPA03000406A (es) * | 2000-07-14 | 2003-06-06 | Wisconsin Alumni Res Found | Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos. |
| US7858602B2 (en) * | 2000-10-16 | 2010-12-28 | Rodriguez Victorio C | Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells |
| US20030195175A1 (en) * | 2002-03-25 | 2003-10-16 | Deluca Hector F. | Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone |
| HK1079766B (zh) | 2002-03-29 | 2007-05-25 | 威斯康星校友研究基金会 | 合成1α-羟基-2-亚甲基-19-去甲-高孕钙化醇的方法 |
| US6846811B2 (en) * | 2002-04-22 | 2005-01-25 | Wisconsin Alumni Research Foundation | (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses |
| WO2004076468A1 (ja) | 2003-02-25 | 2004-09-10 | Kobe Tennenbutsu Kagaku Kabushiki Kaisha | ビタミンｄ誘導体を合成するための新規な中間体 |
| BRPI0414448A (pt) * | 2003-09-19 | 2006-11-14 | Pfizer Prod Inc | composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e um agonista/antagonista de estrogênio |
| US7214671B2 (en) * | 2004-02-19 | 2007-05-08 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases |
| MX2007006261A (es) * | 2004-11-22 | 2007-07-10 | Wisconsin Alumni Res Found | Analogos de 17,20(z)-deshidro vitamina d y sus usos. |
| US20100144671A1 (en) * | 2005-03-04 | 2010-06-10 | Women And Infants Hospital Of Ri, Inc. | Compositions and Methods for Cancer Treatment |
| MX2007013558A (es) * | 2005-05-03 | 2008-01-24 | Wisconsin Alumni Res Found | Compuestos de 19,26,27-trinor-1a,25-dihidroxivitamina d3. |
| US7528122B2 (en) * | 2006-02-02 | 2009-05-05 | Wisconsin Alumni Research Foundation | Vitamin D analog—NEL, methods and uses thereof |
| US7803789B2 (en) * | 2006-02-02 | 2010-09-28 | Wisconsin Alumni Research Foundation | Vitamin D analog—RAK, methods and uses thereof |
| NZ570711A (en) | 2006-04-06 | 2012-10-26 | Wisconsin Alumni Res Found | 2-Substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof |
| MX2008012912A (es) * | 2006-04-06 | 2008-11-26 | Wisconsin Alumni Res Found | Analogos de 2-metilen-1a,25-dihidroxi-19,21-dinorvitamina d3 y sus usos. |
| EP2021321B1 (en) * | 2006-04-06 | 2012-06-20 | Wisconsin Alumni Research Foundation | 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin d3 and uses thereof |
| WO2008035207A2 (en) * | 2006-04-06 | 2008-03-27 | Wisconsin Alumni Research Foundation | 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof |
| NZ570712A (en) * | 2006-04-06 | 2011-11-25 | Wisconsin Alumni Res Found | 2-methylene-1alpha-hydroxy-18,19,21-trinorvitamin D3 analogs and uses thereof |
| EP2001860A2 (en) * | 2006-04-06 | 2008-12-17 | Wisconsin Alumni Research Foundation | 19-nor-vitamin d analogs with 1,2,or 3,2 heterocyclic ring |
| EP2004597B1 (en) * | 2006-04-10 | 2011-01-26 | Wisconsin Alumni Research Foundation | 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds with a 1,1-dimethylpropyl side chain |
| US20080031957A1 (en) * | 2006-05-15 | 2008-02-07 | Deluca Hector F | Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin |
| US8222236B2 (en) * | 2008-07-10 | 2012-07-17 | Wisconsin Alumni Research Foundation | 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs |
| US7888339B2 (en) * | 2008-07-10 | 2011-02-15 | Wisconsin Alumni Research Foundation | 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs |
| US7893043B2 (en) * | 2008-07-10 | 2011-02-22 | Wisconsin Alumni Research Foundation | 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs |
| AU2010281391B2 (en) * | 2009-08-03 | 2015-05-07 | Wisconsin Alumni Research Foundation | Method of preventing renal disease and treating symptoms thereof |
| CA2777938C (en) | 2009-10-21 | 2017-11-14 | Wisconsin Alumni Research Foundation | Method of preventing type 1 diabetes |
| US8604009B2 (en) * | 2010-03-23 | 2013-12-10 | Wisconsin Alumni Research Foundation | (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3 |
| US8664206B2 (en) | 2010-03-23 | 2014-03-04 | Wisconsin Alumni Research Foundation | Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 |
| CA2793727C (en) * | 2010-03-23 | 2017-01-03 | Wisconsin Alumni Research Foundation | Diastereomers of 2-methylene-19-nor-22-methyl-1.alpha.,25-dihydroxyvitamin d3 |
| US20130295083A1 (en) * | 2012-05-02 | 2013-11-07 | Wisconsin Alumni Research Foundation | 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes |
| CN104394871A (zh) | 2012-06-29 | 2015-03-04 | 威斯康星旧生研究基金会 | 2-亚甲基-19-去甲-(20S)-1α,25-二羟基维生素D3治疗继发性甲状旁腺功能亢进的用途 |
| US10369161B2 (en) | 2014-12-30 | 2019-08-06 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism |
| US9539264B2 (en) | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| WO2017184262A1 (en) * | 2016-04-18 | 2017-10-26 | Wisconsin Alumni Research Foundation | Use of 2amd and 2md to treat fibrosis |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL67153A (en) | 1981-11-02 | 1986-12-31 | Res Inst Medicine Chem | Intermediates in the production of vitamin d analogues and method for their production |
| US4666634A (en) | 1984-12-05 | 1987-05-19 | Chugai Seiyaku Kabushiki Kaisha | vitamin D3 derivatives having a substituent at 2-position |
| GB8904154D0 (en) | 1989-02-23 | 1989-04-05 | Leo Pharm Prod Ltd | Chemical compounds |
| NZ232734A (en) | 1989-03-09 | 1991-11-26 | Wisconsin Alumni Res Found | 19-nor vitamin d derivatives and pharmaceutical compositions |
| US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| AU649057B2 (en) | 1990-08-24 | 1994-05-12 | Wisconsin Alumni Research Foundation | Methods and compositions containing vitamin D compounds for improvement of skin conditions |
| ES2123505T3 (es) | 1990-09-07 | 1999-01-16 | Wisconsin Alumni Res Found | Nuevo uso de compuestos de 19-nor-vitamina d 1alfa-hidroxilada para tratar la psoriasis. |
| AU650751B2 (en) | 1991-05-28 | 1994-06-30 | Wisconsin Alumni Research Foundation | Novel synthesis of 19-nor vitamin D compounds |
| US5086191A (en) | 1991-05-28 | 1992-02-04 | Wisconsin Alumni Research Foundation | Intermediates for the synthesis of 19-nor vitamin D compounds |
| EP0619306B1 (en) | 1993-04-05 | 1996-09-11 | Wisconsin Alumni Research Foundation | 19-Nor-vitamin D3 compounds with substituent at 2-position |
| WO1996001811A1 (en) | 1994-07-11 | 1996-01-25 | The Johns-Hopkins University | 2-substituted 1,25-dihydroxyvitamin d3 derivatives |
| US6316642B1 (en) * | 1997-03-17 | 2001-11-13 | Wisconsin Alumni Research Foundation | 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds |
| US5945410A (en) * | 1997-03-17 | 1999-08-31 | Wisconsin Alumni Research Foundation | 2-alkyl-19-nor-vitamin D compounds |
| US5962707A (en) * | 1998-08-18 | 1999-10-05 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D3 compounds with calcemic activity |
-
2000
- 2000-07-14 US US09/616,778 patent/US6306844B1/en not_active Expired - Lifetime
-
2001
- 2001-07-10 AU AU7330301A patent/AU7330301A/xx active Pending
- 2001-07-10 AT AT01952566T patent/ATE359796T1/de active
- 2001-07-10 ES ES01952566T patent/ES2286129T3/es not_active Expired - Lifetime
- 2001-07-10 AU AU2001273303A patent/AU2001273303B8/en not_active Ceased
- 2001-07-10 DK DK01952566T patent/DK1305030T3/da active
- 2001-07-10 DE DE60127964T patent/DE60127964T2/de not_active Expired - Lifetime
- 2001-07-10 EP EP01952566A patent/EP1305030B1/en not_active Expired - Lifetime
- 2001-07-10 CN CNB018155332A patent/CN1250225C/zh not_active Expired - Fee Related
- 2001-07-10 KR KR1020037000542A patent/KR100572958B1/ko not_active Expired - Fee Related
- 2001-07-10 MX MXPA03000405A patent/MXPA03000405A/es active IP Right Grant
- 2001-07-10 JP JP2002511756A patent/JP4955895B2/ja not_active Expired - Fee Related
- 2001-07-10 BR BR0112453-6A patent/BR0112453A/pt not_active Application Discontinuation
- 2001-07-10 NZ NZ524018A patent/NZ524018A/en not_active IP Right Cessation
- 2001-07-10 CA CA002416187A patent/CA2416187A1/en not_active Abandoned
- 2001-07-10 WO PCT/US2001/021660 patent/WO2002005824A1/en not_active Ceased
- 2001-07-10 IL IL15390801A patent/IL153908A0/xx unknown
- 2001-10-19 US US10/045,941 patent/US20020151528A1/en not_active Abandoned
-
2003
- 2003-01-13 IL IL153908A patent/IL153908A/en not_active IP Right Cessation
- 2003-09-29 US US10/673,618 patent/US6939868B2/en not_active Expired - Lifetime
-
2005
- 2005-08-31 US US11/216,951 patent/US20060003973A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK1305030T3 (da) | 2007-09-17 |
| JP4955895B2 (ja) | 2012-06-20 |
| DE60127964D1 (de) | 2007-05-31 |
| US20020151528A1 (en) | 2002-10-17 |
| HK1066487A1 (en) | 2005-03-24 |
| US20040072804A1 (en) | 2004-04-15 |
| CN1501803A (zh) | 2004-06-02 |
| CA2416187A1 (en) | 2002-01-24 |
| KR100572958B1 (ko) | 2006-04-24 |
| ATE359796T1 (de) | 2007-05-15 |
| JP2004509853A (ja) | 2004-04-02 |
| NZ524018A (en) | 2006-06-30 |
| AU2001273303B2 (en) | 2006-02-02 |
| CN1250225C (zh) | 2006-04-12 |
| KR20030016402A (ko) | 2003-02-26 |
| US20060003973A1 (en) | 2006-01-05 |
| AU2001273303B8 (en) | 2006-03-09 |
| AU7330301A (en) | 2002-01-30 |
| US6306844B1 (en) | 2001-10-23 |
| EP1305030A1 (en) | 2003-05-02 |
| EP1305030B1 (en) | 2007-04-18 |
| IL153908A0 (en) | 2003-07-31 |
| DE60127964T2 (de) | 2008-01-17 |
| WO2002005824A1 (en) | 2002-01-24 |
| MXPA03000405A (es) | 2003-06-06 |
| IL153908A (en) | 2009-08-03 |
| BR0112453A (pt) | 2003-08-19 |
| US6939868B2 (en) | 2005-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2286129T3 (es) | Uso de 2-alfa-metil-19-nor-20(s)-1-alfa,25-dihidroxivitamina d3 en sustitucion osea. | |
| ES2274116T3 (es) | 1-alfa-hidroxi-2-metilenj-19-nor-pregnacalciferol y sus usos. | |
| ES2227215T3 (es) | 1 alfa-hidroxi.2.metilen-19-nor-homopregnacalciferol y sus aplicaciones terapeuticas. | |
| AU2001273303A1 (en) | Use of 2alpha-methyl-19-nor-20(s)-1alpha,25-dihydroxyvitamin D3 to increase bone strength | |
| AU2001278888B2 (en) | Use of 2-methylene-19-nor-20(s)-1alpha,25-dihydroxyvitamin D3 to increase bone strength | |
| AU2001278888A1 (en) | Use of 2-methylene-19-nor-20(s)-1alpha,25-dihydroxyvitamin D3 to increase bone strength | |
| ES2399328T3 (es) | Uso de 2-metilen-19-nor-20(S)-1a,25-dihidroxivitamina D3 para la profilaxis de enfermedades óseas | |
| MXPA06003898A (es) | Uso de 2-metilen-19-nor-20(s)-1a, 25-dihidroxivitamina d3 para incrementar las expectativas de vida de seres humanos. | |
| MXPA06009640A (en) | USE OF 2-METHYLENE-19-NOR-20(S)-1alpha,25-DIHYDROXYVITAMIN D3 |